🟢 Ultragenyx is trading 13.99% up in pre-market after FDA granted accelerated approval for GENGLYCOS

Ultragenyx is trading 13.99% up at $29.91 after FDA granted accelerated approval for GENGLYCOS on August 19, 2026.

• GENGLYCOS treats glycogen storage disease type Ia in adults and children aged eight and older, and is Ultragenyx’s first approved gene therapy and fifth FDA-approved product.
• Reuters and company filings confirm the approval, which followed positive Phase 3 data showing reduced cornstarch requirements.
• Move is company-specific; biotech’s 2.27% pre-market gain may reinforce sentiment but does not explain the move.